多西紫杉醇与紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌的疗效比较

目的:比较多西紫杉醇与紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌的疗效。方法:选择2006年6月至2012年6月我院收治的宫颈癌晚期患者180例作为研究对象,依据随机数字表将患者分为紫杉醇组(n=90)和多西紫杉醇组(n=90),两组患者在放疗基础上分别接受紫杉醇135 mg/m~2,每周1次,多西紫杉醇25 mg/m~2,每周1次,4周一疗程,维持两个疗程,比较两组患者的近期疗效、生存时间和毒副作用发生情况。结果:紫杉醇和多西紫杉醇组近期治疗的总有效率分别为81.11%和87.78%,差异无统计学意义(P=0.217);且均未出现进展期的病例。紫杉醇组3年生存率为58.89%,明显低于多西紫杉醇组的75.56%,差异有统计学意义(P=0.017);紫杉醇组骨髓抑制和消化道反应的发生率分别为35.56%和37.78%,明显高于多西紫杉醇组的22.22%和26.67%,差异有统计学意义(均P0.05)。结论:多西紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌能显著提高患者3年生存率,降低毒副作用发生率,且用药量更少,相对安全、合理,患者可耐受,值得进一步临床研究。

Advanced Cervical Cancer: Efficacy Comparison of Docetaxel and Paclitaxelcombined with Cisplatin Chemotherapy and Radiotherapy

Objective:To compare the efficacy of docetaxel and paclitaxel combined with cisplatin chemotherapy andradiotherapy in the treatment of patients with advanced cervical cancer.Methods:A total of 180 patients with advanced cervical cancer,who were treated in Wuhan Commercial Staff and Workers Hospital from June 2006 to June 2012, were chosen as the research subjectsand randomly divided into paclitaxel group(n=90) and docetaxel group(n=90). On the basis of radiotherapy, the two groups were treatedwith paclitaxel 135 mg/m2 once a week, docetaxel 25 mg/m2 once a week respectively, 4 weeks as a course of treatment, maintaining twocourses. Then the short-term efficacy, survival time and side effects in the two groups were compared.Results:Total efficiency ofshort-term efficacy in paclitaxel group and docetaxel group were 81.11% and 87.78% respectively, the difference had no statisticalsignificance (P=0.217), and there was no progressive patients. The survival rate (58.89%) of 3 years in paclitaxel group was significantlylower than that (75.56%) in docetaxel group, the difference was statistically significant (P=0.017). The incidence of bone marrowsuppression (35.56%) and gastrointestinal reaction (37.78%) in the paclitaxel group were significantly higher than those (22.22% and26.67%) in the docetaxel group, the differences were statistically significant (P<0.05).Conclusion:Docetaxel combined with cisplatinchemotherapy and radiotherapy can significantly improve 3-year-survival rate and reduce the incidence of side effects in the treatment ofpatients with advanced cervical cancer, with lower chemotherapy dosage, safety and tolerability for the patients, which is worthy offurther clinical study.